Development and Evaluation of Polymeric In-Situ Implant of PROTACs for NSCLC with IVIVC Integration
Friday, July 18, 2025
8:40 AM – 8:51 AM EDT
Introduction: Lung cancer is the leading cause of cancer-related mortality worldwide1. Current therapies, like EGFR inhibitors, face challenges, including severe side effects, drug resistance, and financial burdens, that lead to patient noncompliance2. Protein-targeting chimeras (PROTACs) represent a novel approach that degrades rather than merely inhibits proteins3. This study explores combining BRD4-degrading PROTAC(BPRO) and EGFR-degrading PROTAC(EPRO) to degrade BRD4 and EGFR, effectively suppressing c-MYC, EGFR, and K-RAS, offering promising therapeutic strategy for NSCLC with diverse genetic profiles.
Learning Objectives:
At the completion of this activity, participants will know
Evaluating BE-PRO synergism with varied EGFR expression NSCLC cell lines.
To access the anticancer efficacy of BE-PRO in 2D and 3D NSCLC models along with optimizing BERD.
Developing IVIVC and evaluating BERD's in-vivo efficacy in the NSCLC tumor-xenograft model.
